cln-978
cln-978: 2 clinical trials tracked.
cln-978 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about cln-978, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren's Disease
Primary endpoint: Safety and Tolerability
Interventionalopen36 targetStarted 2025-10Completion 2029-0314 sites · France, Germany, Italy, United StatesCullinan Therapeutics Inc.
A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Primary endpoint: Safety and tolerability
Interventionalopen24 targetStarted 2025-01Completion 2027-1220 sites · Australia, Bulgaria, France, Georgia…Cullinan Therapeutics Inc.